journal
Journals Antimicrobial Agents and Chemo...

Antimicrobial Agents and Chemotherapy

https://read.qxmd.com/read/38606975/effect-modification-of-dosing-strategy-auc-or-trough-on-aki-associated-with-vancomycin-in-combination-with-piperacillin-tazobactam-or-cefepime-and-meropenem
#1
JOURNAL ARTICLE
Breanne Mefford, Katie L Wallace, J Chris Donaldson, Brittany D Bissell Turpin, Parijat Sen, Aric D Schadler, Lucas J Liu, Melissa L Thompson Bastin
Piperacillin-tazobactam (TZP), cefepime (FEP), or meropenem (MEM) and vancomycin (VAN) are commonly used in combination for sepsis. Studies have shown an increased risk of acute kidney injury (AKI) with TZP and VAN compared to FEP or MEM. VAN guidelines recommend area under the curve (AUC) monitoring over trough (Tr) to minimize the risk of AKI. We investigated the association of AKI and MAKE-30 with the two VAN monitoring strategies when used in combination with TZP or FEP/MEM. Adult patients between 2015 and 2019 with VAN > 72 hours were included...
April 12, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38602418/difficult-to-treat-dtr-pseudomonas-aeruginosa-harboring-verona-integron-metallo-%C3%AE-lactamase-bla-vim-infection-management-and-molecular-analysis
#2
JOURNAL ARTICLE
Ana D Vega, Kailynn DeRonde, Adriana Jimenez, Michael Piazza, Christine Vu, Octavio Martinez, Laura J Rojas, Steven Marshall, Mohamad Yasmin, Robert A Bonomo, Lilian M Abbo
Pseudomonas aeruginosa harboring Verona Integron-encoded metallo-β-lactamase enzymes (VIM-CRPA) have been associated with infection outbreaks in several parts of the world. In the US, however, VIM-CRPA remain rare. Starting in December 2018, we identified a cluster of cases in our institution. Herein, we present our epidemiological investigation and strategies to control/manage these challenging infections. This study was conducted in a large academic healthcare system in Miami, FL, between December 2018 and January 2022...
April 11, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38602413/naphthylisoquinoline-alkaloids-novel-agents-against-the-causative-pathogens-of-eumycetoma-and-actinomycetoma-en-route-to-broad-spectrum-antimycetomal-drugs
#3
JOURNAL ARTICLE
Sami Ahmed Khalid, Shereen Abd Algaffar, Nasir Tajuddeen, Blaise Kimbadi Lombe, Gerhard Bringmann
Mycetoma is a devastating neglected tropical infection of the subcutaneous tissues. It is caused by fungal and bacterial pathogens recognized as eumycetoma and actinomycetoma, respectively. Mycetoma treatment involves diagnosing the causative microorganism as a prerequisite to prescribing a proper medication. Current therapy of fungal eumycetoma causative agents, such as Madurella mycetomatis , consists of long-term antifungal medication with itraconazole followed by surgery, yet with usually unsatisfactory clinical outcomes...
April 11, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38597672/cefadroxil-and-cephalexin-pharmacokinetics-and-pharmacodynamics-in-children-with-musculoskeletal-infections
#4
JOURNAL ARTICLE
Andrew S Haynes, Zixuan Wei, Peter Anderson, Marc H Scheetz, Sarah K Parker, Douglas N Fish
Cephalexin, a first-generation cephalosporin, is the first-line oral therapy for children with musculoskeletal infections due to methicillin-susceptible Staphylococcus aureus (MSSA). Cefadroxil, a similar first-generation cephalosporin, is an attractive alternative to cephalexin given its longer half-life. In this study, we describe the comparative pharmacokinetics (PK) and pharmacodynamics (PD) of cephalexin and cefadroxil in children with musculoskeletal infections. Children aged 6 months to 18 years with a musculoskeletal infection were enrolled in a prospective, open-label, crossover PK study and given single oral doses of cefadroxil (50-75 mg/kg up to 2,000 mg) and cephalexin (50 mg/kg up to 1,375 mg)...
April 10, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38597667/assessing-potential-drug-drug-interactions-between-clofazimine-and-other-frequently-used-agents-to-treat-drug-resistant-tuberculosis
#5
JOURNAL ARTICLE
Allan Kengo, Firdaus Nabeemeeah, Paolo Denti, Ryan Sabet, Gifty Okyere-Manu, Pattamukkil Abraham, Lubbe Weisner, Modiehi Helen Mosala, Sibongile Tshabalala, Janine Scholefield, Juan Eduardo Resendiz-Galvan, Neil A Martinson, Ebrahim Variava
Clofazimine is included in drug regimens to treat rifampicin/drug-resistant tuberculosis (DR-TB), but there is little information about its interaction with other drugs in DR-TB regimens. We evaluated the pharmacokinetic interaction between clofazimine and isoniazid, linezolid, levofloxacin, and cycloserine, dosed as terizidone. Newly diagnosed adults with DR-TB at Klerksdorp/Tshepong Hospital, South Africa, were started on the then-standard treatment with clofazimine temporarily excluded for the initial 2 weeks...
April 10, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38597636/comparison-of-lumefantrine-mefloquine-and-piperaquine-concentrations-between-capillary-plasma-and-venous-plasma-samples-in-pregnant-women-with-uncomplicated-falciparum-and-vivax-malaria
#6
JOURNAL ARTICLE
Makoto Saito, Pornpimon Wilaisrisak, Mupawjay Pimanpanarak, Jacher Viladpai-Nguen, Moo Kho Paw, Urairat Koesukwiwat, Joel Tarning, Nicholas J White, Francois Nosten, Rose McGready
UNLABELLED: Capillary samples offer practical benefits compared with venous samples for the measurement of drug concentrations, but the relationship between the two measures varies between different drugs. We measured the concentrations of lumefantrine, mefloquine, piperaquine in 270 pairs of venous plasma and concurrent capillary plasma samples collected from 270 pregnant women with uncomplicated falciparum or vivax malaria. The median and range of venous plasma concentrations included in this study were 447...
April 10, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38591854/the-virtue-of-training-extending-phage-host-spectra-against-vancomycin-resistant-enterococcus-faecium-strains-using-the-appelmans-method
#7
JOURNAL ARTICLE
Julien Lossouarn, Elsa Beurrier, Astrid Bouteau, Elisabeth Moncaut, Maria Sir Silmane, Heïdi Portalier, Asma Zouari, Vincent Cattoir, Pascale Serror, Marie-Agnès Petit
Phage therapy has (re)emerged as a serious possibility for combating multidrug-resistant bacterial infections, including those caused by vancomycin-resistant Enterococcus faecium strains. These opportunistic pathogens belong to a specific clonal complex 17, against which relatively few phages have been screened. We isolated a collection of 21 virulent phages growing on these vancomycin-resistant isolates. Each of these phages harbored a typical narrow plaquing host range, lysing at most 5 strains and covering together 10 strains of our panel of 14 clinical isolates...
April 9, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38587412/transcriptomic-responses-to-antibiotic-exposure-in-mycobacterium-tuberculosis
#8
JOURNAL ARTICLE
Husain Poonawala, Yu Zhang, Sravya Kuchibhotla, Anna G Green, Daniela Maria Cirillo, Federico Di Marco, Andrea Spitlaeri, Paolo Miotto, Maha R Farhat
Transcriptional responses in bacteria following antibiotic exposure offer insights into antibiotic mechanism of action, bacterial responses, and characterization of antimicrobial resistance. We aimed to define the transcriptional antibiotic response (TAR) in Mycobacterium tuberculosis (Mtb) isolates for clinically relevant drugs by pooling and analyzing Mtb microarray and RNA-seq data sets. We generated 99 antibiotic transcription profiles across 17 antibiotics, with 76% of profiles generated using 3-24 hours of antibiotic exposure and 49% within one doubling of the WHO antibiotic critical concentration...
April 8, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38587392/influenza-c-virus-susceptibility-to-antivirals-with-different-mechanisms-of-action
#9
JOURNAL ARTICLE
Anton Chesnokov, Andrei A Ivashchenko, Yoko Matsuzaki, Emi Takashita, Vasiliy P Mishin, Alexandre V Ivachtchenko, Larisa V Gubareva
Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC50 8-22 nM) against type C viruses from six lineages. Banana lectin and a monoclonal antibody, YA3, targeting the hemagglutinin-esterase protein effectively neutralized some, but not all, type C viruses...
April 8, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38587391/extended-blood-stage-sensitivity-profiles-of-plasmodium-cynomolgi-to-doxycycline-and-tafenoquine-as-a-model-for-plasmodium-vivax
#10
JOURNAL ARTICLE
Peter Christensen, Rosy Cinzah, Rossarin Suwanarusk, Adeline Chiew Yen Chua, Osamu Kaneko, Dennis E Kyle, Htin Lin Aung, Jessica Matheson, Pablo Bifani, Laurent Rénia, Gregory M Cook, Georges Snounou, Bruce Russell
Testing Plasmodium vivax antimicrobial sensitivity is limited to ex vivo schizont maturation assays, which preclude determining the IC50s of delayed action antimalarials such as doxycycline. Using Plasmodium cynomolgi as a model for P. vivax , we determined the physiologically significant delayed death effect induced by doxycycline [IC50(96 h) , 1,401 ± 607 nM]. As expected, IC50(96 h) to chloroquine (20.4 nM), piperaquine (12.6 µM), and tafenoquine (1,424 nM) were not affected by extended exposure...
April 8, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38587380/population-pharmacokinetic-modeling-of-dolutegravir-lamivudine-to-support-a-once-daily-fixed-dose-combination-regimen-in-virologically-suppressed-adults-living-with-hiv-1
#11
JOURNAL ARTICLE
Hardik Chandasana, Rajendra Singh, Kimberly Adkison, Mounir Ait-Khaled, Teodora Pene Dumitrescu
UNLABELLED: A fixed-dose combination (FDC) of 50 mg dolutegravir and 300 mg lamivudine is indicated for the treatment of HIV-1 infection. This analysis aimed to characterize the population pharmacokinetics (PK) of dolutegravir and lamivudine based on data from a phase 3 study (TANGO) in virologically suppressed adults living with HIV-1 switching to dolutegravir/lamivudine FDC. These analyses included 362 participants who contributed 2,629 dolutegravir and 2,611 lamivudine samples collected over 48 weeks...
April 8, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38578080/prospective-validation-of-a-model-informed-precision-dosing-tool-for-vancomycin-treatment-in-neonates
#12
JOURNAL ARTICLE
Riste Kalamees, Hiie Soeorg, Mari-Liis Ilmoja, Kadri Margus, Irja Lutsar, Tuuli Metsvaht
We recruited 48 neonates (50 vancomycin treatment episodes) in a prospective study to validate a model-informed precision dosing (MIPD) software. The initial vancomycin dose was based on a population pharmacokinetic model and adjusted every 36-48 h. Compared with a historical control group of 53 neonates (65 episodes), the achievement of a target trough concentration of 10-15 mg/L improved from 37% in the study to 62% in the MIPD group ( P = 0.01), with no difference in side effects.
April 5, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38572960/efflux-pump-effects-on-levofloxacin-resistance-in-mycobacterium-abscessus
#13
JOURNAL ARTICLE
Tianlu Teng, Suting Chen, Fengmin Huo, Junnan Jia, Liping Zhao, Guanglu Jiang, Fen Wang, Naihui Chu, Hairong Huang
Mycobacterium abscessus (M. abscessus ) inherently displays resistance to most antibiotics, with the underlying drug resistance mechanisms remaining largely unexplored. Efflux pump is believed to play an important role in mediating drug resistance. The current study examined the potential of efflux pump inhibitors to reverse levofloxacin (LFX) resistance in M. abscessus . The reference strain of M. abscessus (ATCC19977) and 60 clinical isolates, including 41 M. abscessus subsp. abscessus and 19 M . abscessus subsp...
April 4, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38572959/abc-transporter-inhibition-by-beauvericin-partially-overcomes-drug-resistance-in-leishmania-tropica
#14
JOURNAL ARTICLE
Charbel Al Khoury, Sergio Thoumi, Sima Tokajian, Aia Sinno, Georges Nemer, Mark El Beyrouthy, Kelven Rahy
Leishmaniasis is a neglected tropical disease infecting the world's poorest populations. Miltefosine (ML) remains the primary oral drug against the cutaneous form of leishmaniasis. The ATP-binding cassette (ABC) transporters are key players in the xenobiotic efflux, and their inhibition could enhance the therapeutic index. In this study, the ability of beauvericin (BEA) to overcome ABC transporter-mediated resistance of Leishmania tropica to ML was assessed. In addition, the transcription profile of genes involved in resistance acquisition to ML was inspected...
April 4, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38567976/characterization-of-acinetobacter-baumannii-calcoaceticus-complex-isolates-and-microbiological-outcome-for-patients-treated-with-sulbactam-durlobactam-in-a-phase-3-trial-attack
#15
JOURNAL ARTICLE
Alita A Miller, Samir H Moussa, Sarah M McLeod
Acinetobacter baumannii-calcoaceticu s complex (ABC) causes severe, difficult-to-treat infections that are frequently antibiotic resistant. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat ABC infections, including those caused by multidrug-resistant strains. In a global, pathogen-specific, randomized, controlled phase 3 trial (ATTACK), the efficacy and safety of SUL-DUR were compared to colistin, both dosed with imipenem-cilastatin as background therapy, in patients with serious infections caused by carbapenem-resistant ABC...
April 3, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38567956/the-ptk2-pma1-pathway-enhances-tolerance-to-terbinafine-in-trichophyton-rubrum
#16
JOURNAL ARTICLE
Masaki Ishii, Tsuyoshi Yamada, Kazuki Ishikawa, Koji Ichinose, Michel Monod, Shinya Ohata
The increasing prevalence of dermatophyte resistance to terbinafine, a key drug in the treatment of dermatophytosis, represents a significant obstacle to treatment. Trichophyton rubrum is the most commonly isolated fungus in dermatophytosis. In T. rubrum , we identified TERG_07844, a gene encoding a previously uncharacterized putative protein kinase, as an ortholog of budding yeast Saccharomyces cerevisiae polyamine transport kinase 2 (Ptk2), and found that T. rubrum Ptk2 (TrPtk2) is involved in terbinafine tolerance...
April 3, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38564665/nationwide-genome-surveillance-of-carbapenem-resistant-pseudomonas-aeruginosa-in-japan
#17
JOURNAL ARTICLE
Hirokazu Yano, Wataru Hayashi, Sayoko Kawakami, Sadao Aoki, Eiko Anzai, Hui Zuo, Norikazu Kitamura, Aki Hirabayashi, Toshiki Kajihara, Shizuo Kayama, Yo Sugawara, Koji Yahara, Motoyuki Sugai
Japan is a country with an approximate 10% prevalence rate of carbapenem-resistant Pseudomonas aeruginosa (CRPA). Currently, a comprehensive overview of the genotype and phenotype patterns of CRPA in Japan is lacking. Herein, we conducted genome sequencing and quantitative antimicrobial susceptibility testing for 382 meropenem-resistant CRPA isolates that were collected from 78 hospitals across Japan from 2019 to 2020. CRPA exhibited susceptibility rates of 52.9%, 26.4%, and 88.0% against piperacillin-tazobactam, ciprofloxacin, and amikacin, respectively, whereas 27...
April 2, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38563751/a-randomized-assessors-blind-clinical-trial-to-evaluate-the-safety-and-the-efficacy-of-albendazole-alone-and-in-combination-with-mebendazole-or-pyrantel-for-the-treatment-of-trichuris-trichiura-infection-in-school-aged-children-in-lambar%C3%A3-n%C3%A3-and-surroundings
#18
JOURNAL ARTICLE
Paul Alvyn Nguema Moure, Moustapha Nzamba Maloum, Gédéon Prince Manouana, Roméo-Aimé Laclong Lontchi, Mirabeau Mbong Ngwese, Jean Ronald Edoa, Jeannot Fréjus Zinsou, Brice Meulah, Saidou Mahmoudou, Elsy Mirna N'noh Dansou, Yabo Josiane Honkpehedji, Bayode Romeo Adegbite, Selidji Todagbe Agnandji, Michael Ramharter, Bertrand Lell, Steffen Borrmann, Peter G Kremsner, Jean Claude Dejon-Agobé, Ayôla Akim Adegnika
Helminthiasis remains a public health issue in endemic areas. Various drugs have been proposed to improve efficacy against helminths. The study aimed to assess the safety and efficacy of three different anthelmintic combinations to treat Trichuris trichiura infections. We conducted a randomized assessors-blind clinical trial involving children aged 2-17 years with T. trichiura . Participants were randomly assigned to one of three treatment arms. On the first and third days, all participants got albendazole 400 mg, and on the second day, albendazole (arm A), mebendazole 500 mg (arm B), or pyrantel 125 mg/kg (arm C)...
April 2, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38557235/-acinetobacter-baumannii-international-clone-2-co-producing-oxa-23-ndm-1-and-arma-emerging-in-south-america
#19
LETTER
Thais Martins-Gonçalves, Julia S Pimenta, Herrison Fontana, Fernanda Esposito, Gregory Melocco, Karine Dantas, Felipe Vásquez-Ponce, Floristher E Carrara, Eliana C Vespero, Nilton Lincopan
No abstract text is available yet for this article.
April 1, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38557171/-in-vitro-activity-of-cefoxitin-imipenem-meropenem-and-ceftaroline-in-combination-with-vaborbactam-against-mycobacterium-abscessus
#20
JOURNAL ARTICLE
Liang Chen, Elena Shashkina, Natalia Kurepina, Vinicius Calado Nogueira de Moura, Charles L Daley, Barry N Kreiswirth
Mycobacterium abscessus (MAB) infections pose a growing public health threat. Here, we assessed the in vitro activity of the boronic acid-based β-lactamase inhibitor, vaborbactam, with different β-lactams against 100 clinical MAB isolates. Enhanced activity was observed with meropenem and ceftaroline with vaborbactam (1- and >4-fold MIC50 /90 reduction). CRISPRi-mediated bla MAB gene knockdown showed a fourfold MIC reduction to ceftaroline but not the other β-lactams. Our findings demonstrate vaborbactam's potential in combination therapy against MAB infections...
April 1, 2024: Antimicrobial Agents and Chemotherapy
journal
journal
22731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.